Agnès Hagège | Search arXiv

arXiv2026

Unlocking the Full Potential of Taylor Dispersion Analysis Through Advanced Detection

Today, pharmaceutical sciences rely on a wide range of innovative therapeutics of varying sizes: nanoparticles, proteins, antibodies, and nanocarriers for drug delivery. Measuring their size is one of the crucial parameters in their characterization, to ensure drug safety, stability, and effectiveness. Over the past two decades, Taylor Dispersion Analysis has emerged as an important sizing method. Its scope of application is perfectly suited to the sizes of these therapeutics. By design, it can be coupled with a wide range of detectors, and extensive research has been conducted in this field. In this review, we will present an overview of the studies conducted, and discuss how the application drives the choice of one detector or another (size measurement, aggregation studies, interaction studies, and other analyses, performed in both simple biological buffers and in more complex media, particularly serum) and makes Taylor Dispersion Analysis a highly versatile tool.

q-bio.BM↗

arXiv2024

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

physics.bio-ph↗

arXiv2023

Tuning ultrasmall theranostic nanoparticles for MRI contrast and radiation dose amplification

Background: The introduction of magnetic resonance (MR)-guided radiation treatment planning has opened a new space for theranostic nanoparticles to reduce acute toxicity while improving local control. In this work, second-generation AGuIX nanoparticles (AGuIX-Bi) are synthesized and validated. AGuIX-Bi are shown to maintain MR positive contrast while further amplifying the radiation dose by the replacement of some Gd$^{3+}$ cations with higher Z Bi$^{3+}$. These next-generation nanoparticles are based on the AGuIX platform, which is currently being evaluated in multiple Phase II clinical trials in combination with radiotherapy. Methods: In this clinically scalable methodology, AGuIX is used as an initial chelation platform to exchange Gd$^{3+}$ for Bi$^{3+}$. AGuIX-Bi nanoparticles are synthesized with three ratios of Gd/Bi, each maintaining MR contrast while further amplifying radiation dose relative to Bi$^{3+}$. Safety, efficacy, and theranostic potential of the nanoparticles were evaluated in vitro and in vivo in a human non-small cell lung cancer model. Results: We demonstrated that increasing Bi$^{3+}$ in the nanoparticles is associated with more DNA damage and improves in vivo efficacy with a statistically significant delay in tumor growth and 33% complete regression for the largest Bi/Gd ratio tested. The addition of Bi$^{3+}$ by our synthetic method leads to nanoparticles that present slightly altered pharmacokinetics and lengthening of the period of high tumor accumulation with no observed evidence of toxicity. Conclusions: We confirmed the safety and enhanced efficacy of AGuIX-Bi with radiation therapy at the selected ratio of 30Gd/70Bi. These results provide crucial evidence towards patient translation.

cond-mat.mtrl-sci↗